Neoplasms Clinical Trials
A listing of Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found 187 clinical trials
UPCC 13418: A Multicenter Open-Label Phase 1b Study to Assess Safety and Efficacy of Venetoclax in Combination with Gilteritinib in Subjects with Relapsed/Refractory Acute Myeloid Leukemia
The purposes of this study are to see if the study drugs, venetoclax and gilteritinib can be safely and effectively combined for the treatment of patients with acute myeloid leukemia (AML) that has returned after prior treatment, or has failed to respond to prior treatment and identify potential biomarkers.
UPCC 31218: A prospective multicentre randomised controlled study evaluating SIR-Spheres Y-90 resin microspheres preceding standard cisplatin-gemcitabine (CIS-GEM) chemotherapy versus CIS-GEM chemotherapy alone as first-line treatment of patients with unresectable intrahepatic CholangioCArcinoma (SIRCCA)
The main purpose of this research study is to find out whether Selective Internal Radiation Therapy (SIRT) preceding a standard chemotherapy treatment can improve survival in patients with cholangiocarcinoma in the liver, compared to chemotherapy alone.
A Phase 3 Randomized 3-Part Study To Investigate The Efficacy And Safety Of Dupilumab In Adult And Adolescent Patients With Eosinophilic Esophagitis
Brief Summary: The primary objectives of the study by study part are: Part A: To determine the treatment effect of dupilumab compared with placebo in adult and adolescent patients with EoE after 24 weeks of treatment as assessed by histological and clinical measures, and to inform/confirm the final sample size …
UPCC 43419: Prospective Study of Immune Biomarkers in Patients with Multiple Myeloma
The objective of this exploratory observational cohort study is to obtain blood samples - and in some cases, bone marrow aspirate samples - from patients with multiple myeloma for study in the laboratory.
Managed Access Program (MAP) to provide access to CTL019 for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release
The purpose of this Treatment Plan is to allow access to tisagenlecleucel (CTL019) for eligible patients diagnosed with acute lymphoblastic leukemia (ALL) or large b-cell lymphomas who are unable to receive commercially manufactured product due to failure of the incoming apheresis material or outgoing product to meet the commercial specifications …
2 march upen 6
This is a randomized, open-label, parallel group study to determine the optimal dose of CART-19 cells (of the two dose levels being assessed (1-5x10xE8 vs. 1-5x10xE7 CART-19 cells). This trial will be conducted in two stages. In Stage 2, the selected dose cohort will be expanded to enroll additional subjects, …
2 march upen 11
This is a randomized, open-label, parallel group study to determine the optimal dose of CART-19 cells (of the two dose levels being assessed (1-5x10xE8 vs. 1-5x10xE7 CART-19 cells). This trial will be conducted in two stages. In Stage 2, the selected dose cohort will be expanded to enroll additional subjects, …
2 march upen 12
This is a randomized, open-label, parallel group study to determine the optimal dose of CART-19 cells (of the two dose levels being assessed (1-5x10xE8 vs. 1-5x10xE7 CART-19 cells). This trial will be conducted in two stages. In Stage 2, the selected dose cohort will be expanded to enroll additional subjects, …
2 march upen 14
This is a randomized, open-label, parallel group study to determine the optimal dose of CART-19 cells (of the two dose levels being assessed (1-5x10xE8 vs. 1-5x10xE7 CART-19 cells). This trial will be conducted in two stages. In Stage 2, the selected dose cohort will be expanded to enroll additional subjects, …
2 march upen 15
This is a randomized, open-label, parallel group study to determine the optimal dose of CART-19 cells (of the two dose levels being assessed (1-5x10xE8 vs. 1-5x10xE7 CART-19 cells). This trial will be conducted in two stages. In Stage 2, the selected dose cohort will be expanded to enroll additional subjects, …
